Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 300 of 5804
-
Smart wristbands could spot strokes before It's too late
Diagnosis Recruiting nowThe Neuralert monitoring system, a non-invasive device worn on each wrist, is designed to provide continuous monitoring and expedited recognition of stroke by identifying asymmetry in the extremities, facilitating patient treatment and improving outcomes. This study is designed t…
Phase: NA • Sponsor: Neuralert Technologies LLC • Aim: Diagnosis
Last updated Jun 27, 2026 12:02 UTC
-
Immune cells armed to hunt down hidden leukemia
Disease control Recruiting nowThe purpose of this study is to understand the safety and estimate the efficacy of combining anti-CD3 x anti-CD33 bispecific antibody (CD33Bi) armed fresh peripheral blood mononuclear cells (CD33Bi FPBMC) for patients with acute myeloid leukemia (AML) or myelodysplastic syndrome …
Phase: PHASE1 • Sponsor: University of Virginia • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
New drug duo aims to shrink head and neck tumors before surgery
Disease control Recruiting nowThis trial is to evaluate the safety and efficacy of ficerafusp alfa in combination with pembrolizumab prior to surgical resection in participants with resectable, high-risk, locoregionally advanced, PD-L1-positive squamous cell carcinoma of the head and neck (HNSCC). The names …
Phase: PHASE2 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC
-
New hope for lung injury: drug may repair radiation and immunotherapy damage
Disease control Recruiting nowRadiation-induced lung injury (RILI) is one of the most common thoracic-radiotherapy complications, with an incidence as high as 31.4 %. Multiple studies have shown that RILI can adversely affect patient prognosis by disrupting treatment schedules. Moreover, the widespread clinic…
Phase: PHASE2, PHASE3 • Sponsor: Beijing Continent Pharmaceutical Co, Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Could custom blood pressure goals save more hearts?
Disease control Recruiting nowCardiogenic shock is a life-threatening condition characterized by inadequate cardiac output, leading to organ hypoperfusion and high mortality. Maintaining mean arterial pressure (MAP) is crucial, but standard targets may be insufficient due to venous congestion. Central venous …
Phase: NA • Sponsor: CMC Ambroise Paré • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
New blood test may guide better breast cancer treatment
Disease control Recruiting nowThis is an open-label phase 2 study to evaluate the pCR rate in patients diagnosed with HER2 positive breast cancer treated on an adaptive clinical trial design. Tumors will undergo testing using a novel molecular phosphoprotein-based biomarker assay, HER2 Activation Response Pr…
Phase: PHASE2 • Sponsor: Rutgers, The State University of New Jersey • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New hope for advanced kidney cancer: experimental drug pumitamig enters human trials
Disease control Recruiting nowThe purpose of this study is to evaluate the safety, tolerability, and efficacy of Pumitamig alone or in combination with Ipilimumab or Cabozantinib in participants with advanced Renal Cell Carcinoma (RCC)
Phase: PHASE1, PHASE2 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Jul 22, 2026 00:00 UTC
-
Promising drug cocktail aims to wipe out breast cancer before surgery
Disease control Not yet recruitingTo evaluate the efficacy and safety of Serplulimab in combination with Trastuzumab Restuzumab for the neoadjuvant treatment of triple-negative breast cancer, aiming to provide evidence for optimizing the strategy of combining immunotherapy with ADC drugs in the neoadjuvant settin…
Phase: PHASE2 • Sponsor: Xijing Hospital • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC
-
Can a Pre-Surgery immune boost stop liver Cancer's return?
Disease control Not yet recruitingOur study aims to evaluate the benefit of the administration of immunotherapy (atezolizumab), in patients with hepatocellular carcinoma (HCC), prior surgical resection of the tumor. HCC is the most prevalent primary liver cancer, responsible for nearly 800,000 deaths annually, m…
Phase: PHASE3 • Sponsor: University of Geneva, Switzerland • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
New stroke treatment could help patients with medium clots
Disease control Not yet recruitingDATE-MeVO is an investigator-initiated, multicenter, prospective, randomized controlled, open-label, blinded endpoint (PROBE) clinical trial aiming at evaluating the efficacy and safety of tenecteplase combined with standard medications in acute ischemic stroke patients with medi…
Phase: PHASE3 • Sponsor: Southwest Hospital, China • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
Laser zaps brain tumors in kids without open surgery
Disease control Recruiting nowThis study aims to evaluate the efficacy of Laser Interstitial Thermal Therapy (LITT) in treating recurrent or progressive, low-grade gliomas (LGG) in pediatric, adolescent and young adult patients.
Phase: NA • Sponsor: University of California, San Francisco • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
-
AI-Powered wearables could warn of heart attacks before they happen
Diagnosis Not yet recruitingAcute myocardial infarction (AMI), as the leading cause of death among cardiovascular diseases, has its diagnosis and treatment efficiency directly affecting survival. Although the current diagnosis and treatment system has significantly improved in-hospital outcomes, delays in s…
Sponsor: Beijing Anzhen Hospital • Aim: Diagnosis
Last updated Jun 27, 2026 12:01 UTC
-
Artificial bronchus implant aims to open blocked airways in severe emphysema
Disease control Recruiting nowA study taking place at multiple sites in the United States, Europe and Brazil to evaluate how well a new therapy for severe COPD/emphysema works, and how safe it is.
Phase: NA • Sponsor: Pulmair Medical, Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Could this pill ease Alzheimer's psychosis? large trial underway
Symptom relief Recruiting nowThe purpose of this study is to evaluate KarXT + KarX-EC as a treatment for psychosis associated with Alzheimer's disease.
Phase: PHASE3 • Sponsor: Bristol-Myers Squibb • Aim: Symptom relief
Last updated Jul 02, 2026 00:00 UTC
-
New radiation therapy targets kidney cancer cells
Disease control Recruiting nowMulticenter Phase 3 study of 177Lu-TLX250 in adult participants with CAIX-expressing advanced, relapsed or recurrent clear cell renal cell carcinoma (ccRCC). Part 1 will evaluate two dosing regimens to determine the recommended Phase 3 dose (RP3D). Part 2 will compare 177Lu-TLX25…
Phase: PHASE3 • Sponsor: Telix Pharmaceuticals (Innovations) Pty Limited • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
-
New combo therapy aims to outsmart pancreatic Cancer's defenses
Disease control Recruiting nowThe investigators hypothesize that CD11b agonism reprograms the tumor microenvironment (TME) to overcome resistance to checkpoint immunotherapy in pancreatic ductal adenocarcinoma (PDAC). Therefore, the investigators propose an open label phase I/II clinical trial of ONT01 with g…
Phase: PHASE1, PHASE2 • Sponsor: Washington University School of Medicine • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
New drug cocktail shows promise for shrinking lung tumors before surgery
Disease control Recruiting nowThe goal of this clinical trial is to learn if Ensartinib combined with chemotherapy works as a neoadjuvant treatment for patients with stage II-IIIB (N2) ALK-positive non-small cell lung cancer (NSCLC). It will also learn about the safety of this combination therapy. The main qu…
Phase: PHASE1, PHASE2 • Sponsor: Tang-Du Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
-
Double dose hope: new stroke study tests second clot buster
Disease control Recruiting nowWhile intravenous thrombolysis (IVT) within 4.5 hours is the standard medical reperfusion therapy, its efficacy is limited, particularly for large or medium vessel occlusions (LVO/MeVO), with low recanalization rates for IVT with rt-PA. The newer thrombolytic agent, tenecteplase …
Phase: PHASE2 • Sponsor: General Hospital of Shenyang Military Region • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
-
New hope for advanced head and neck cancer: drug combo trial launches
Disease control ENROLLING_BY_INVITATIONThis research study is for people who have head and neck cancer that has come back or spread to other places in the body.
Phase: PHASE2 • Sponsor: SWOG Cancer Research Network • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
Triple-Drug attack on liver cancer shows promise in early trial
Disease control Recruiting nowThe goal of this clinical trial is to evaluate the safety, tolerability, and preliminary efficacy of a combination therapy involving TACE, sintilimab, bevacizumab, and ipilimumab N01 for the treatment of advanced hepatocellular carcinoma (HCC). It also aims to explore the potenti…
Phase: PHASE2 • Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC